2026-04-05T10:41:53Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/96622024-12-13T10:42:10Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer Juliachs, Mercè Pujals-Pruneda, Mireia Meo-Evoli, Nathalie Duran, Juan M Parés, Mireia Suñol, Anna Mendez Fernández, Olga Sánchez Pla, Alex Canals Suris, Francesc Bellio, Chiara Zamora, Esther Saura, Cristina Villanueva Cardús, Josep Mama - Càncer - Tractament Marcadors tumorals Medicaments antineoplàstics - Ús terapèutic DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy ANATOMY::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante ANATOMÍA::células::células cultivadas::línea celular::línea celular tumoral COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales Breast cancer; Response biomarkers; Secretome Càncer de mama; Biomarcadors de resposta; Secretoma Cáncer de mama; Biomarcadores de respuesta; Secretoma There is a great need for non-invasive tools that inform of an early molecular response to cancer therapeutic treatment. Here, we tested the hypothesis that proteolytically resistant proteins could be candidate circulating tumor biomarkers for cancer therapy. Proteins resistant to proteolysis are drastically under-sampled by current proteomic workflows. These proteins could be reliable sensors for the response to therapy since they are likely to stay longer in circulation. We selected manganese superoxide dismutase (SOD2), a mitochondrial redox enzyme, from a screening of proteolytic resistant proteins in breast cancer (BC). First, we confirmed the robustness of SOD2 and determined that its proteolytic resistance is mediated by its quaternary protein structure. We also proved that the release of SOD2 upon chemotherapy treatment correlates with cell death in BC cells. Then, after confirming that SOD2 is very stable in human serum, we sought to measure its circulating levels in a cohort of BC patients undergoing neoadjuvant therapy. The results showed that circulating levels of SOD2 increased when patients responded to the treatment according to the tumor shrinkage during neoadjuvant chemotherapy. Therefore, the measurement of SOD2 levels in plasma could improve the non-invasive monitoring of the therapeutic treatment in breast cancer patients. The identification of circulating biomarkers linked to the tumor cell death induced by treatment could be useful for monitoring the action of the large number of cancer drugs currently used in clinics. We envision that our approach could help uncover candidate tumor biomarkers to measure a tumor’s response to cancer therapy in real time by sampling the tumor throughout the course of treatment. This work was funded by Servier. 2023-11-08T10:23:23Z 2023-11-08T10:23:23Z 2023-06-06T08:01:22Z 2023-06-06T08:01:22Z 2022-08-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/9662 Cancers;14(16) https://doi.org/10.3390/cancers14163858 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess MDPI Scientia